Liquid biopsies in the management of bladder cancer

Next-generation biomarkers for diagnosis, surveillance, and treatment-response prediction

Yu Yang, Catherine R. Miller, Antonio Lopez-Beltran, Rodolfo Montironi, Monica Cheng, Shaobo Zhang, Michael Koch, Hristos Kaimakliotis, Liang Cheng

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

In this review, we discuss the types of liquid biopsies currently available and their recent and potential clinical applications, especially as they relate to the detection of molecular biomarkers of bladder cancer. The advances in research using high-throughput, next-generation genomic techniques have identified a number of promising molecular biomarkers of bladder urothelial carcinoma. Liquid biopsy has recently received enormous attention as a potential tool for real-time monitoring of disease status in cancer patients, and genomic profiles are reported to closely match those of corresponding tumors. The procedure is noninvasive and easily repeated and allows monitoring during treatment and detection of different genomic alterations that are potentially accessible to targeted therapy or are associated with treatment resistance in bladder cancer patients. Moreover, liquid biopsy is a tool that allows rapid access to biomarker assessment in patients for whom solid biopsies are not available. Liquid biopsy will be widely applied to daily clinical practice and serve as an important tool for the screening, surveillance, prediction of outcomes, and selection of effective targeted therapies in bladder carcinoma.

Original languageEnglish (US)
Pages (from-to)389-401
Number of pages13
JournalCritical Reviews in Oncogenesis
Volume22
Issue number5-6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Biopsy
Urinary Bladder
Carcinoma
Therapeutics
Neoplasms
Research

Keywords

  • Biomarker
  • Bladder
  • Cell-free tumor DNA
  • Circulating tumor cells
  • Liquid biopsy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Liquid biopsies in the management of bladder cancer : Next-generation biomarkers for diagnosis, surveillance, and treatment-response prediction. / Yang, Yu; Miller, Catherine R.; Lopez-Beltran, Antonio; Montironi, Rodolfo; Cheng, Monica; Zhang, Shaobo; Koch, Michael; Kaimakliotis, Hristos; Cheng, Liang.

In: Critical Reviews in Oncogenesis, Vol. 22, No. 5-6, 01.01.2017, p. 389-401.

Research output: Contribution to journalReview article

@article{ed0172d467324c5f9a90070b819b7180,
title = "Liquid biopsies in the management of bladder cancer: Next-generation biomarkers for diagnosis, surveillance, and treatment-response prediction",
abstract = "In this review, we discuss the types of liquid biopsies currently available and their recent and potential clinical applications, especially as they relate to the detection of molecular biomarkers of bladder cancer. The advances in research using high-throughput, next-generation genomic techniques have identified a number of promising molecular biomarkers of bladder urothelial carcinoma. Liquid biopsy has recently received enormous attention as a potential tool for real-time monitoring of disease status in cancer patients, and genomic profiles are reported to closely match those of corresponding tumors. The procedure is noninvasive and easily repeated and allows monitoring during treatment and detection of different genomic alterations that are potentially accessible to targeted therapy or are associated with treatment resistance in bladder cancer patients. Moreover, liquid biopsy is a tool that allows rapid access to biomarker assessment in patients for whom solid biopsies are not available. Liquid biopsy will be widely applied to daily clinical practice and serve as an important tool for the screening, surveillance, prediction of outcomes, and selection of effective targeted therapies in bladder carcinoma.",
keywords = "Biomarker, Bladder, Cell-free tumor DNA, Circulating tumor cells, Liquid biopsy",
author = "Yu Yang and Miller, {Catherine R.} and Antonio Lopez-Beltran and Rodolfo Montironi and Monica Cheng and Shaobo Zhang and Michael Koch and Hristos Kaimakliotis and Liang Cheng",
year = "2017",
month = "1",
day = "1",
doi = "10.1615/CRITREVONCOG.2017020803",
language = "English (US)",
volume = "22",
pages = "389--401",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "5-6",

}

TY - JOUR

T1 - Liquid biopsies in the management of bladder cancer

T2 - Next-generation biomarkers for diagnosis, surveillance, and treatment-response prediction

AU - Yang, Yu

AU - Miller, Catherine R.

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Cheng, Monica

AU - Zhang, Shaobo

AU - Koch, Michael

AU - Kaimakliotis, Hristos

AU - Cheng, Liang

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In this review, we discuss the types of liquid biopsies currently available and their recent and potential clinical applications, especially as they relate to the detection of molecular biomarkers of bladder cancer. The advances in research using high-throughput, next-generation genomic techniques have identified a number of promising molecular biomarkers of bladder urothelial carcinoma. Liquid biopsy has recently received enormous attention as a potential tool for real-time monitoring of disease status in cancer patients, and genomic profiles are reported to closely match those of corresponding tumors. The procedure is noninvasive and easily repeated and allows monitoring during treatment and detection of different genomic alterations that are potentially accessible to targeted therapy or are associated with treatment resistance in bladder cancer patients. Moreover, liquid biopsy is a tool that allows rapid access to biomarker assessment in patients for whom solid biopsies are not available. Liquid biopsy will be widely applied to daily clinical practice and serve as an important tool for the screening, surveillance, prediction of outcomes, and selection of effective targeted therapies in bladder carcinoma.

AB - In this review, we discuss the types of liquid biopsies currently available and their recent and potential clinical applications, especially as they relate to the detection of molecular biomarkers of bladder cancer. The advances in research using high-throughput, next-generation genomic techniques have identified a number of promising molecular biomarkers of bladder urothelial carcinoma. Liquid biopsy has recently received enormous attention as a potential tool for real-time monitoring of disease status in cancer patients, and genomic profiles are reported to closely match those of corresponding tumors. The procedure is noninvasive and easily repeated and allows monitoring during treatment and detection of different genomic alterations that are potentially accessible to targeted therapy or are associated with treatment resistance in bladder cancer patients. Moreover, liquid biopsy is a tool that allows rapid access to biomarker assessment in patients for whom solid biopsies are not available. Liquid biopsy will be widely applied to daily clinical practice and serve as an important tool for the screening, surveillance, prediction of outcomes, and selection of effective targeted therapies in bladder carcinoma.

KW - Biomarker

KW - Bladder

KW - Cell-free tumor DNA

KW - Circulating tumor cells

KW - Liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85052535057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052535057&partnerID=8YFLogxK

U2 - 10.1615/CRITREVONCOG.2017020803

DO - 10.1615/CRITREVONCOG.2017020803

M3 - Review article

VL - 22

SP - 389

EP - 401

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 5-6

ER -